🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares

Published 12/05/2024, 06:30 AM
JAZZ
-

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), recently sold 2,000 ordinary shares of the company. The shares were sold at an average price of $121.17 each, amounting to a total transaction value of $242,340. Following this sale, Cozadd retains ownership of 427,025 shares. According to InvestingPro data, Jazz Pharmaceuticals maintains impressive financial health with industry-leading gross profit margins of 93% and strong liquidity, with current assets exceeding short-term obligations by more than 4 times.

This transaction was conducted under a pre-arranged trading plan, commonly known as a Rule 10b5-1 plan, which allows company insiders to sell a predetermined number of shares at a predetermined time. Additionally, Cozadd recently acquired 49 ordinary shares through an employee stock purchase plan at the end of November. InvestingPro analysis suggests the stock is currently undervalued, with 8 additional exclusive insights available to subscribers, including detailed information about management's aggressive share buyback program and the company's financial outlook.

In other recent news, Jazz Pharmaceuticals has announced a strategic amendment to its credit agreement, increasing its revolving credit facility from $500 million to $885 million and extending the maturity date from 2026 to 2029. This move is expected to enhance the company's financial flexibility. Additionally, Jazz Pharmaceuticals has seen notable developments in its drug portfolio. The patient base for Xywav, one of the company's key medications, has increased, a development that was positively received by analysts from Baird.

In response to this growth, Baird has raised the price target for Jazz Pharmaceuticals from $154 to $162. Concurrently, Piper Sandler has slightly decreased its price target for the company to $163, while Jefferies has raised its stock price target to $160. These adjustments are based on the company's attractive valuation and projected revenue and earnings growth rates.

Furthermore, the U.S. Food and Drug Administration has recently granted accelerated approval to zanidatamab, a therapy developed by Jazz Pharmaceuticals for patients with previously treated, unresectable or metastatic HER2+ biliary tract cancer. This approval marks a significant regulatory milestone for the company. Jazz Pharmaceuticals is also awaiting phase 3 topline progression-free survival results for zanidatamab, expected in the second quarter of 2025. These are the recent developments for Jazz Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.